EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Branford, S
  • Kamel-Reid, S
  • Bendit, I
  • Etienne, G
  • Guerci-Bresler, A
  • Hughes, TP
  • Lipton, JH
  • Leber, Brian
  • Spector, N
  • Steegmann, JL
  • Acharya, S
  • Collins, L
  • Dalal, D
  • Cervantes, F

publication date

  • June 1, 2014